se gb
First In Class Potential

Aprea AB

Aprea is developing pharmaceuticals that reactivates the tumor suppressor protein p53, which is impaired in many instances of cancer.
First In Class Potential

BioArctic Neuroscience AB

BioArctic Neuroscience develops new treatment methods and diagnostic tools for Alzheimer’s disease and other neurodegenerative diseases.
First In Class Potential

Dilafor AB

Dilafor is developing pharmaceuticals against protracted labor based on modified heparin.
First In Class Potential

Forendo Pharma Oy

Forendo Pharma develops novel pharmaceutical treatments for endometriosis and for male patients with low testosterone levels.

Inhalation Sciences Sweden AB

Inhalation Sciences develops and sells proprietary tools and services that accelerate drug discovery timelines and reduce attrition rates in the clinical phase when developing pharmaceuticals intended for inhalation administration.

Lipidor AB

Lipidor develops innovative technologies for lipid-based topical pharmaceutical delivery.

Modus Therapeutics AB

Modus is developing innovative treatments for patients with sickle-cell disease based on a heparin analogue, sevuparin. Sickle-cell disease is a painful, inherited blood disorder affecting millions of people around the globe.

OssDsign AB

OssDsign is developing pioneering implants for bone healing with an initial focus on skull surgery.

Promimic AB

Promimic develops and markets a nano-based surface applied to dental and bone implants for improved integration to bone and soft tissue
First In Class Potential

Umecrine Cognition AB

Umecrine Cognition develops pharmaceuticals against mild Alzheimer’s disease and mild cognitive disorders.

Financial/Passive Investments